anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To determine whether machine learning (ML) techniques developed using registry data could predict which patients will achieve minimum clinically important difference (MCID) on the International Hip Outcome Tool 12 (iHOT-12) patient-reported outcome measures (PROMs) after arthroscopic management of femoroacetabular impingement syndrome (FAIS). And secondly to determine which preoperative factors contribute to the predictive power of these models.
METHODS: A retrospective cohort of patients was selected from the UK's Non-Arthroplasty Hip Registry. Inclusion criteria were a diagnosis of FAIS, management via an arthroscopic procedure, and a minimum follow-up of 6 months after index surgery from August 2012 to June 2021. Exclusion criteria were for non-arthroscopic procedures and patients without FAIS. ML models were developed to predict MCID attainment. Model performance was assessed using the area under the receiver operating characteristic curve (AUROC).
RESULTS: In total, 1,917 patients were included. The random forest, logistic regression, neural network, support vector machine, and gradient boosting models had AUROC 0.75 (0.68-0.81), 0.69 (0.63-0.76), 0.69 (0.63-0.76), 0.70 (0.64-0.77), and 0.70 (0.64-0.77), respectively. Demographic factors and disease features did not confer a high predictive performance. Baseline PROM scores alone provided comparable predictive performance to the whole dataset models. Both EuroQoL 5-Dimension 5-Level and iHOT-12 baseline scores and iHOT-12 baseline scores alone provided AUROC of 0.74 (0.68-0.80) and 0.72 (0.65-0.78), respectively, with random forest models.
CONCLUSIONS: ML models were able to predict with fair accuracy attainment of MCID on the iHOT-12 at 6-month postoperative assessment. The most successful models used all patient variables, all baseline PROMs, and baseline iHOT-12 responses. These models are not sufficiently accurate to warrant routine use in the clinic currently.
LEVEL OF EVIDENCE: Level III, retrospective cohort design; prognostic study.
PURPOSE: A cosmetic formulation containing Limnophila conferta extract is provided to prevent or delay skin aging signal and ensure nail promotion effect. CONSTITUTION: A cosmetic formulation contains Limnophila conferta extract. The Limnophila conferta extract is isolated from plant whole body, root, stem, leaf, flower, seed or bud. The extract is isolated using polar solvent or mixture of polar solvent. The mixture of polar solvent is water, C1-C4 alcohol, glycol or their mixture. The cosmetic composition contains the cosmetic formulation in a cosmetically acceptable carrier in a solution or dispersion solution.
The present invention provides a use of a composition in preparing a cosmetic having moisturizing effect, wherein the composition comprises a P-113 peptide, wherein the P-113 peptide comprises the sequence of SEQ ID NO: 1. It is hypoallergenic and non-cytotoxic, which means it does not cause harms or allergies to the skin and can be used as an ingredient of cosmetic products. The P-113 peptide fragment has moisture absorption and moisture retention effects, therefore it can be formulated with other ingredients of moisturizing cosmetic products, enhancing the moisturizing effect of other moisturizing ingredients. In addition, the P-113 peptide fragment is capable of inhibiting the production of MMP-9 and thus decreases collagen degradation, thereby achieving the anti-wrinkle and anti-aging effects. The cosmetic of the present invention comprises not only the peptide, but also active ingredients of cosmetic products and essence liquid formulations. Accordingly, it not only provides major effects such as moisturizing and anti-wrinkle, but also enhances other composite functions, such as astringent effect, whitening, anti-aging, anti-oxidation or skin tissue activation.
Risperidone (Ris) is a second-generation antipsychotic that belongs to the chemical class of benzisoxazole derivatives. 9-Hydroxy (9OH-) Ris is well known among the six reported metabolites of Ris and had been examined using not only blood but also other matrices, but the other five metabolites reported such as benzisoxazole ring-cleaved Ris (c-Ris) and c-9OH-Ris had been detected only in blood, urine and feces. In the present work, large peaks of c-Ris and c-9OH-Ris were detected in the liver, kidney, cerebrum, blood, pericardial fluid, bile and urine obtained from two cadavers. There is a potential that c-Ris and c-9OH-Ris will be good markers to prove Ris consumption in forensic toxicology cases. For example, the peak ratios of c-Ris against the parent Ris in the kidney and blood were as high as 3.9 and 3.6 in cadaver 1; and 7.0 and 7.9 in cadaver 2, respectively. In addition to the previously reported six metabolites, five new metabolites such as dehydrogenated-Ris, 7-keto-Ris and three benzisoxazole ring-cleaved metabolites were disclosed in the present work, and the pathways for the totally eleven metabolites detected in human solid tissues and body fluids have also been proposed, because such pathways were neither reported nor discussed previously.
Neck pain can be a long-lasting condition, Between half and three quarters of patients with neck pain will experience recurrence within 1-5 years. Costs for the society due to neck pain are consequently high. Neck pain (NP) is one of the common musculoskeletal problems. NP can be caused by the stress over the musculoskeletal system due to postural disorders and may also be associated with other causes such as intervertebral disc herniation, nerve compression, or fracture. Musculoskeletal pain due to trigger points is one of the most prevalent reasons for patients to seek treatment. The aim of physical therapy treatment in patient with myofascial pain syndrome is to reduce the pain and restore normal function. Most physical therapy treatments for MPS are targeted to the deactivation of MTrPs. Physical therapy techniques include manual therapies; such as ischemic compression, spray and stretch, strain and counter strain, muscle energy techniques, trigger point pressure release, transverse friction massage; needling therapies, and other techniques such as thermotherapy, ultrasound therapy , phonophoresis and laser therapy.Due to the semi-solid properties, a special method is needed for transdermal permeation of lidocaine. Therefore, many studies have focused on enhancing the level of transdermal permeation by either changing the physiochemical properties of lidocaine or using physical modalities In particular, there has been considerable interest in transdermal permeation using various methods based on the idea that the amount and depth of transdermal permeation can be increased using various physical modalities. patients with mechanical neck pain will be allocated randomly into three equal groups; group A will receive phonophoresis and traditional therapy, group B will receive high power pain thresholdand traditional therapy and group C will receive traditional therapy
An improved informed consent system and method is disclosed. The system comprises a visual component, an auditory component, and a textual component. The visual component consists of a visual representation of the surgery, preferably in three-dimensional form. The auditory component consists of a narration integral with the visual component that explains the visual representation of the surgery. The textual component consists of a summary of each complication associated with the surgery. The system includes an input mechanism for inputting an acknowledgment of each complication, as well as each complication encountered by the patient during the surgery, and a storage mechanism for electronically storing the patient's acknowledgment of each complication. The visual, auditory, and textual components are preferably integrally combined to form a single informed consent system.
Orofacial pain can significantly affect physical, psychological, and overall quality of life. This study aimed to compare the effectiveness of combining photobiomodulation (PBM) with orofacial myofunctional therapy (OMT) in managing orofacial pain disorders. An electronic search of randomized controlled trials in electronic databases was performed until March 2024. Randomized controlled trials (RCTs) focusing on PBM and OMT for the management of orofacial pain were included. Risk of bias across individual studies was performed using the Cochrane risk of bias tool for interventions. A total of 10 RCTs were included, out of which 7 RCTs revealed that the combined approach of PBM and OMT had a more pronounced impact on diminishing pain and enhancing functional activity in patients with orofacial disorders. One study reported significant increases in pressure pain threshold for TMJ, masseter, and anterior temporalis muscles at both sides in the post-treatment compared with the pre-treatment in both groups. The risk of bias was low in 7, moderate in 2, and high in 1 study. The efficacy of a combined modality treatment of PBM with OMT for orofacial pain disorder shows promising results. However, further randomized controlled trials with extended follow-up periods standardized PBM and OMT parameters are warranted to obtain firm conclusions.
Half of the participants in either arm (bike-share or public transportation) will be randomly assigned to either begin the intervention immediately, or be placed on a waitlist, serving as a control arm. The waitlist will be 8 weeks long, the same timeline as the intervention. After the eighth week, participants assigned to the waitlist will then begin the intervention for the next 8 weeks. Participants assigned to starting the intervention immediately will then be placed on the waitlist for the second-8 weeks of the total study enrollment.
Vasopressor medications for circulatory shock have historically been administered through central venous catheters due to concern for extravasation injury when given peripherally. However, recent studies have demonstrated the safety of peripheral administration of vasopressor medications at lower doses and for a limited duration. Peripheral use of vasopressors is appealing to both patients and providers, as obtaining central access is an invasive procedure associated with the risk of pneumothorax, bleeding, and infection. Furthermore, waiting to initiate these medications until central access is obtained can lead to delays in care. Conversely, valid concerns remain regarding the risk of tissue extravasation associated with peripheral vasopressors, which can be life and limb threatening. We discuss the guidelines and data for optimal dose, duration, intravenous line (IV) size, IV location, and nursing IV site monitoring for peripheral vasopressors. We then explore adverse events associated with peripheral vasopressors. Finally, we describe how this practice change may impact hospital medicine providers.
Cyclobenzaprine hydrochloride is a white, crystalline tricyclic amine salt with the empirical formula C 20H 21N • HCl and a molecular weight of 311.9. It has a melting point of 217°C, and a pK a of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. 

Cyclobenzaprine HCl is designated chemically as 3-( 5H-dibenzo[ a,d]cyclohepten-5-ylidene)- N, N-dimethyl-1-propanamine hydrochloride, and has the following structural formula: 

Cyclobenzaprine Hydrochloride Tablets, USP are supplied as 10 mg tablets for oral administration.

Each tablet contains the following inactive ingredients: croscarmellose sodium, FD&C Yellow #6, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide; 10 mg tablets contain D&C Yellow #10 and polysorbate.
Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.
This invention provides a parakeratosis inhibitor, pore reducing agent and skin roughness preventive/ameliorating agent. It possesses the functions of parakeratosis inhibition, pore reduction, skin roughness prevention/amelioration, etc. It further provides an external composition for skin with these capabilities. This invention provides a parakeratosis inhibitor, and a pore reducing agent. It comprises at least one compound selected from the group that includes a glycine derivative, an aminodicarboxylic acid derivative, an acylaminodicarboxylic acid derivative, a pyrrolidinecarboxylic acid derivative, a piperidinecarboxylic acid derivative, a hexamethyleneiminecarboxylic acid derivative, a beta-alanine derivative and salts of these derivatives. Further, it provides a parakeratosis inhibitor, a pore reducing agent and a skin roughness preventive/ameliorating agent. Furthermore, it comprises at least one compound selected from the group that includes specified glycine derivatives and salts thereof, and specified aminosulfuric acid derivatives and salts thereof. In addition, it provides external compositions for skin comprising these compounds.
Beginning within 84 days after surgery, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Benign thyroid disease with a nodule equal or lesser than 4 cm in diameter of any gender or ethnical origin. Half of these patients will undergo either bipolar or conventional thyroidectomy.
This solution is for intravenous use only.

Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.

In the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of 0.9% sodium chloride (154 mEq each of sodium and chloride).

There is no specific pediatric dose. The dose is dependent on weight, clinical condition and laboratory results. Follow recommendations of appropriate pediatric reference text. (See PRECAUTIONS, Pediatric Use.)

Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.

0.9% Sodium Chloride Injection USP may also be administered intravascularly as a priming fluid in hemodialysis procedures.

When Sodium Chloride Injection USP is used as a diluent for infusion of compatible drug additives, refer to dosage and administration information accompanying additive drugs.

Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Recent studies have proved lamivudine a very potent antiviral drug in suppressing viral replication and improving hepatic necro-inflammation with minimal adverse effects in HBeAg positive chronic hepatitis B patients. The efficacy of lamivudine in HBeAg positivce Asian patients has been weel established. However, the evidence in HBeAg negative patients is limited.

In the absence of HBeAg seroconversion, guidance on the clinical management of HBeAg negative hepatitis B patitents treated with lamivudine and data on the efficacy of lamivudine in controlling pre-core HBV disease long-term is still needed. Existing data in HBeAg negative/ HBV DNA positive HBV demonstrate clear and statisticallysignificant serological benefit of lamivudine over placebo during treatment. Limited sustained response was observed post-treatment following a one year treatment period. Whether these results can be applied to patients in Asia is uncertain. This study is therefore intended to further assess te efficacy profile over an extended treatment period in the Asian population.
Starting at Day 1 of the Randomized Evaluation Period, the ALXN1850 group will receive bodyweight dependent doses of either 20mg, 35mg or 50mg of ALXN1850 once every 2 weeks (q2w) via SC injection, for 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.
F gene-deficient virus virions are successfully recovered by using an F gene-deficient Sendai virus genomic cDNA. Further, F  gene-deficient infectious viral particles are successfully constructed by using F-expressing cells as helper cells . Also, F gene and HN gene-deficient virus virions are successfully recovered by using a virus genomic cDNA deficient in both F gene and HN gene.  Further, F gene and HN gene-deficient infectious viral particles are successfully produced by using F- and HN-expressing cells as helper cells . A virus deficient in F gene and HN gene and having F protein is constructed by using F-expressing cells as helper cells. Further, a VSV-G pseudo type virus is successfully constructed by using VSV-G-expressing cells . Techniques for constructing these deficient viruses contribute to the development of vectors of Paramyxoviridae usable in gene therapy.
Subjects will receive a single infusion of ex vivo expanded Treg product (2 x 10\^6). Insulin will be continued as a routine therapy.
Subjects with primary or secondary hypertension and normotensive control subjects. In addition haemodynamic recordings to 50 subjects suffering from chronic fatigue syndrome will be performed.
PROBLEM TO BE SOLVED: To make it possible to correct an electronic clinical chart, to easily make an entry into the electronic clinical card, to prevent the electronic clinical chart from being altered, and to speedily adapt to the revision of the law and regulations. SOLUTION: A plurality of treatment plans are held for one mouth to make medical treatment efficient. When a clinical chart is corrected by deleting a line of the clinical chart, the data are not deleted but a double line is drawn over the line. A hand-written illustration can be inserted. In this case, text data at the pasting place are so shifted not to overlap with the illustration and divided by the illustration. If the lower divided part cannot be put in the same page of the clinical sheet, a new page is inserted and the remaining data are moved thereto. If the illustration cannot be put in the remaining part of the page of the clinical chart, a new page is inserted and the illustration is drawn. Blank line symbols are inserted into clinical chart blank lines formed at the lower parts of all pages.  A periodontics examination table is combined with an arbitrary line of the clinical chart and referred to. A processing program itself is sent as text data to a user by using the Internet. A prescription format is held in the form of text data and can easily be altered.
FIELD: medicinal preparations. SUBSTANCE: pharmaceutical composition contains agonists/antagonists of estrogen and prostaglandins or agonists/antagonists of prostaglandin. The invention also deals with sets of said compositions for treatment of osseous disturbances, including osteoporosis. The composition increases (preserves) osseous mass, and, as a result, osteoporosis is prevented, decelerated and/or regressed as well as related osseous disturbances. EFFECT: higher efficiency. 33 cl
Beta-glucan-rich barley has been shown to improve glycemic response, reduce hunger and increase satiety. Nutrient-dense grain mixtures that include a new cultivar of barley (Sustagrain, Ardent Mills, LLC) with exceptionally high dietary fiber content may help individuals meet their dietary fiber needs while minimizing the rapid increase in blood glucose following the consumption of a refined grain product. The primary objective of this study was to compare the effects of five different test meals containing varying amounts of whole-grain barley and refined white rice to white bread on post-prandial blood glucose concentrations. A secondary aim was to evaluate changes in self-reported hunger and satiety following the consumption of each treatment. This study was a single-site, blinded, randomized crossover trial among 24 healthy adults. Each participant consumed the following treatments: 100% Sustagrain barley flakes, 100% Sustagrain steel cut barley , an 80/20 rice-steel cut Sustagrain barley mix, a 50/50 rice-steel cut Sustagrain barley mix, 100% rice, and white bread.
Patients receive sorafenib tosylate as in group 1. Patients also receive oral tipifarnib twice daily on days 1-21.
The invention particularly discloses a kind of pharmaceutical compositions and preparation method thereof for treating eczema；The present invention includes following raw material for treating the pharmaceutical composition of eczema: emulsifier, moisturizer, penetration enhancer, matrix and Chinese medical extract.The pharmaceutical composition preparation method for treating eczema comprises the steps of: that S1. is impregnated Chinese medicine with distilled water, 30~45min of time；S2. the Chinese medicine after immersion is subjected to 40~50min of refluxing extraction；S3. the dregs of a decoction separate, and collect filtrate；S4. filtrate is collected, filter residue is abandoned；S5. filtrate is freeze-dried again, obtains Chinese medical concrete；S6. other ingredients are added to stirring and dissolving in 35~45 DEG C of distilled water in order, Chinese medical concrete is then added inward again；S7. above-mentioned solution is stirred dissolution, and be filtered；S8. after filtering, homogeneous is carried out；S9. then under the conditions of 5~10 DEG C, place 30~60min to get.
PURPOSE: To simply distribute a dosing amt. of an aerosol drug to the lungs of a large animal such as a horse without causing pain in order to treat a disease such as a recurrent airway obstruction disease. CONSTITUTION: The distal end part of an intratracheal insertion tubular intranasal insertion tube 16 is inserted into the nasopharyngeal duck of a large animal through the external naris thereof and, when air flows toward the lungs of the large animal through the lumen 28 of the intranasal insertion tube 16, a dosing amt. of an atomized aerosol drug is discharged into the lumen 28 of the intranasal insertion tube 16. A dosing amt. of the atomized drug is carried by this inwardly flowing air to be distributed to the lungs of the large animal.
A handle is composed of a left handlebar having a left gripping section, and a right handlebar having a right gripping section. The two gripping sections extend along a longitudinal axle of the handle and are respectively longer than the breath of the user's hand, i.e. the user can hold one of optional positions of the handle. Each of the two gripping sections has at least one contact face extending along the surface thereof. Each of the contact faces is electrically conductive but not in electrical connection with the others. The contact faces are respectively electrically connected to a particular processor of an exercise apparatus, such that the processor can scan the user's human electrical signals, like frequency of potential difference or impedance, and further transform the signals into corresponding human physiological characteristics.
Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h. investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.